Corpus Intelligence IC Memo — SAN JOAQUIN VALLEY REHAB HOSPITAL 2026-04-26 09:36 UTC
IC Memo — SAN JOAQUIN VALLEY REHAB HOSPITAL
Investment Committee Memorandum | CA | 62 beds | Grade D | EBITDA uplift $2.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SAN JOAQUIN VALLEY REHAB HOSPITAL

CCN 053032 | FRESNO, CA | 62 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

SAN JOAQUIN VALLEY REHAB HOSPITAL is a 62-bed rural/critical access in FRESNO, CA with $39.3M in net patient revenue and a -5.7% operating margin. The hospital serves a payer mix of 65.5% Medicare, 2.1% Medicaid, and 32.5% commercial.

Thesis: Turnaround. Our ML models identify $2.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -5.7% to 1.6% (+736bps).

Net Revenue HCRIS$39.3M
Current EBITDA COMPUTED$-2.2M
Operating Margin COMPUTED-5.7%
Occupancy HCRIS75.7%
Revenue / Bed COMPUTED$634K
Net-to-Gross HCRIS42.0%
Distress Probability ML45.3%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
128
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -5.7% places it below the state median. Among 128 size-comparable peers (31-124 beds), the median margin is -6.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (31-124), prioritizing same-state peers. 128 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SAN JOAQUIN VALLEY REHAB HOSPI (Target)CA62$39.3M-5.7%
CONTRA COSTA REGIONAL MEDICAL CA124$595.0M-29.2%
RANCHO LOS AMIGOS NATL.REHAB.CCA83$512.6M41.9%
USC NORRIS CANCER HOSPITALCA60$468.7M19.1%
SUTTER SANTA ROSA REGIONAL HOSCA124$374.4M-0.2%
KFH - FREMONTCA100$296.2M-6.6%
QUEEN OF THE VALLEY MEDICAL CECA119$293.8M-16.7%
MERCY HOSPITAL OF FOLSOMCA106$287.8M17.0%
MARSHALL HOSPITALCA111$286.0M-5.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$826K+210bp18mo
Cost to Collect4.5%2.5%$787K+200bp12mo
Denial Rate Reduction12.0%6.5%$779K+198bp12mo
A/R Days Reduction5200.0%3800.0%$479K+122bp9mo
Clean Claim Rate88.0%96.0%$25K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$826K
Cost to Collect
$787K
Denial Rate Reduction
$779K
A/R Days Reduction
$479K
Clean Claim Rate
$25K
Total EBITDA Uplift$2.9M
Current EBITDA$-2.2M
+ RCM Uplift+$2.9M
Pro Forma EBITDA$646K
Current Margin-5.7%
Pro Forma Margin1.6%
WC Released (1x)$1.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-3.5M$14.1M0.00x-100.0%
Base (11x exit)10.0x11.0x$-3.5M$14.4M0.00x-100.0%
Bull Case9.0x11.0x$-3.1M$22.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-3.1M$24.0M0.00x-100.0%
Bear Case11.0x10.0x$-3.8M$763K0.00x-100.0%
Bear (11x exit)11.0x11.0x$-3.8M$-397K0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumHeavy Medicare dependenceMedicare comprises 65.5% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 128 hospitals with 31-124 beds
  • Same-state prioritization (n=129)
  • Comp margins: P25=-23.8% / P50=-6.2% / P75=1.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.